T Lymphocyte-Specific Deletion of SHP1 and SHP2 Promotes Activation-Induced Cell Death of CD4+ T Cells and Impairs Antitumor Response
Connor Foster, Jasper Du, Oscar J. Pundel, Mitchell J. Geer, Ryan C. Ripert, Jia Liu, Taylor A. Heim, Kiyomi Y. Araki, Amanda W. Lund, Jun Wang, Benjamin G. Neel
This study shows that deleting SHP1 and SHP2 in T cells increases CD4+ T cell activation-induced cell death and reduces antitumor responses, with SHP2 loss enhancing anti-PD-1 therapy.
Proceedings of the National Academy of Sciences · Jul 14, 2025Peer-reviewedImmunology